KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)

Lonial, Sagar; Oliveira, M.; Yimer, Habte; Mateos, María‐Victoria; Rifkin, Robert M.; Schjesvold, Fredrik; San-Miguel, Jesús F.; Ghori, Razi; Marinello, Patricia; Jagannath, Sundar

doi:10.1093/annonc/mdw525.51

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the observation of stable disease in 63% [85] in the heavily pretreated relapsed-refractory MM population suggests potential effectiveness in combinatorial settings. Clinical trials are underway to explore the effectiveness of PD-1 and PD-L1 inhibition in combination with proteasome inhibitors and immunomodulatory agents (IMiDs) in pretreated [87] and therapy-naïve MM patients [88]. Reports of early results show significant efficacy in the relapsed-refractory population when Pembrolizumab is combined with an IMiD (50% ORR with lenalidomide plus dexamethasone (KEYNOTE-023), 60% ORR with pomalidomide and dexamethasone (KEYNOTE-183).…”

Section: Future Directionsmentioning

confidence: 99%

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Ghosh

Mailankody

Giralt

et al. 2017

Leukemia & Lymphoma

View full text Add to dashboard Cite

While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies.

show abstract

Section: Future Directionsmentioning

confidence: 99%

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Ghosh

Mailankody

Giralt

et al. 2017

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis

Piechotta

Jakob

Langer

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundMultiple myeloma is a bone marrow-based hematological malignancy accounting for approximately two per cent of cancers. First-line treatment for transplant-ineligible individuals consists of multiple drug 18/04 Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with tran... 18/04 Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with tran... * V stands for 'Velcade®', the proprietary name of bortezomib. ** R stands for 'Revlimid®', the proprietary name of lenalidomide.Nowadays, the recommended treatment for adults with transplant-ineligible newly diagnosed multiple myeloma (NDMM) is either a double-or a triple-drug combination therapy (Kumar 2018; Moreau 2017), consisting of: immunomodulatory drug (R or T) in combination with a glucocorticoid (D, P) or glucocorticoid and alkylating agent (CD, CP or MP) proteasome inhibitor (V) in combination with a glucocorticoid (D, P) or glucocorticoid and alkylating agent (CD, CP or MP) immunomodulatory drug (R or T) in combination with proteasome inhibitor (V), and a glucocorticoid (D, P) or glucocorticoid and alkylating agent (CD, CP or MP) Regimens, which include either an immunomodulatory drug or a proteasome inhibitor will be referred to as double-drug combinations. We will refer to triple-drug combinations, when a immunomodulatory drug and a proteasome inhibitor is included in the regimen.Combinations of these interventions at any dose and by any route were compared to each other in a full network. We included trials with any treatment duration and divided treatment regimens between fixed and continuous therapies (Description of the intervention).To increase the amount of potential comparisons and to strengthen the network, we also included studies comparing the described double-or triple-drug combinations to the former standard treatment MP. As the aim of this review was to inform an application for the WHO list of essential medicines, the focus of this review was to compare the effectiveness and safety of V, R, and T. Therefore, if we identified additional new drugs for first-line treatment of multiple myeloma, these were excluded from the network and this review.We assumed that any participant that meets the inclusion criteria was, in principle, equally likely to be randomised to any of the eligible interventions. We planned to group interventions by evaluating different drug doses together as one drug of interest, according to the product characteristics.We excluded trials including participants receiving neither V, R, or T (triple or double combination) in at least one treatment arm, and trials including participants receiving no corticosteroid. We excluded trials evaluating the effectiveness and safety of the interventions of interest for supportive treatment during stem cell transplantation, or maintenance therapy, or both. Medications used to treat myeloma in subsequent lines of therapy might be the same as for first-line treatment, but to ens...

show abstract

KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)

Cited by 2 publications

References 0 publications

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis

Contact Info

Product

Resources

About